BringmeON Eveline Lescrinier

Prof. Dr. BringmeON Eveline Lescrinier

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2020 in Processes
Verified
Journal Article
Open access
PDF file
Outi Salo-AhenOuti Salo-Ahen
Outi Salo-Ahen
IAIda Alanko
Ida Alanko
Rajendra BhadaneRajendra Bhadane
Rajendra Bhadane
ABAlexandre M.J.J. Bonvin
Alexandre M.J.J. Bonvin
RHRodrigo Vargas Honorato
Rodrigo Vargas Honorato
MVMichiel Vanmeert
Michiel Vanmeert
Molecular dynamics (MD) simulations have become increasingly useful in the modern drug development process. In this review, we give a broad overview of the current application possibilities of MD in drug discovery and pharmaceutical development. Starting from the target validation step of the drug development process, we give several examples of how MD studies can give important insights into the dynamics and function of identified drug targets such as sirtuins, RAS proteins, or intrinsically disordered proteins. The role of MD in antibody design is also reviewed. In the lead discovery and lead optimization phases, MD facilitates the evaluation of the binding energetics and kinetics of the ligand-receptor interactions, therefore guiding the choice of the best candidate molecules for further development. The importance of considering the biological lipid bilayer environment in the MD simulations of membrane proteins is also discussed, using G-protein coupled receptors and ion channels as well as the drug-metabolizing cytochrome P450 enzymes as relevant examples. Lastly, we discuss the emerging role of MD simulations in facilitating the pharmaceutical formulation development of drugs and candidate drugs. Specifically, we look at how MD can be used in studying the crystalline and amorphous solids, the stability of amorphous drug or drug-polymer formulations, and drug solubility. Moreover, since nanoparticle drug formulations are of great interest in the field of drug delivery research, different applications of nano-particle simulations are also briefly summarized using multiple recent studies as examples. In the future, the role of MD simulations in facilitating the drug development process is likely to grow substantially with the increasing computer power and advancements in the development of force fields and enhanced MD methodologies.

23 August 2000 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
BVBirgit Verbeure
Birgit Verbeure
ILIngrid Luyten
Ingrid Luyten
BLBringmeON Eveline Lescrinier
BringmeON Eveline Lescrinier
MFMatthias Froeyen
Matthias Froeyen
PHPiet Herdewijn
Piet Herdewijn

5 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
DKDaniela Brigitte Krentz
Daniela Brigitte Krentz
KZKatharina Zenger
Katharina Zenger
MAMartin Alberer
Martin Alberer
SFSandra Felten
Sandra Felten
MBMichèle Bergmann
Michèle Bergmann
KHKatrin Hartmann
Katrin Hartmann
Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn® in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn®. Eighteen cats with FIP were prospectively followed up while being treated orally for 84 days. Values of key parameters on each examination day were compared to values before treatment initiation using linear mixed-effect models. Xraphconn® displayed high virucidal activity in cell culture. All cats recovered with dramatic improvement of clinical and laboratory parameters and massive reduction in viral loads within the first few days of treatment without serious adverse effects. Oral treatment with Xraphconn® containing GS-441524 was highly effective for FIP without causing serious adverse effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potential effective treatment option for other severe coronavirus-associated diseases across species.

1 March 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JJJan Jordens
Jan Jordens
VJVeerle Janssens
Veerle Janssens
SLSari Longin
Sari Longin
ISIlse Stevens
Ilse Stevens
EMEllen Martens
Ellen Martens
CHChristine Van Hoof
Christine Van Hoof
The protein phosphatase 2A (PP2A) phosphatase activator (PTPA) is an essential protein involved in the regulation of PP2A and the PP2A-like enzymes. In this study we demonstrate that PTPA and its yeast homologues Ypa1 and Ypa2 can induce a conformational change in some model substrates. Using these model substrates in different assays with and without helper proteases, this isomerase activity is similar to the isomerase activity of FKBP12, the human cyclophilin A, and one of its yeast homologs Cpr7 but dissimilar to the isomerase activity of Pin1. However, neither FKBP12 nor Cpr7 can reactivate the inactive form of PP2A. Therefore, PTPA belongs to a novel peptidyl-prolyl cis/trans-isomerase (PPIase) family. The PPIase activity of PTPA correlates with its activating activity since both are stimulated by the presence of Mg2+ATP, and a PTPA mutant (Delta208-213) with 400-fold less activity in the activation reaction of PP2A also showed almost no PPIase activity. The point mutant Asp205 --> Gly (in Ypa1) identified this amino acid as essential for both activities. Moreover, PTPA dissociates the inactive form from the complex with the PP2A methylesterase. Finally, Pro190 in the catalytic subunit of PP2A (PP2AC) could be identified as the target Pro isomerized by PTPA/Mg2+ATP since among the 14 Pro residues present in 12 synthesized peptides representing the microenvironments of these prolines in PP2AC, only Pro190 could be isomerized by PTPA/Mg2+ATP. This Pro190 is present in a predicted loop structure near the catalytic center of PP2AC and, if mutated into a Phe, the phosphatase is inactive and can no longer be activated by PTPA/Mg2+ATP.

17 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Joleen MasscheleinJoleen Masschelein
Joleen Masschelein
WMWesley Mattheus
Wesley Mattheus
LGLing-Jie Gao
Ling-Jie Gao
PMPieter Moons
Pieter Moons
Rob Van HoudtRob Van Houdt
Rob Van Houdt
Rob LavigneRob Lavigne
Rob Lavigne
Serratia plymuthica strain RVH1, initially isolated from an industrial food processing environment, displays potent antimicrobial activity towards a broad spectrum of Gram-positive and Gram-negative bacterial pathogens. Isolation and subsequent structure determination of bioactive molecules led to the identification of two polyamino antibiotics with the same molecular structure as zeamine and zeamine II as well as a third, closely related analogue, designated zeamine I. The gene cluster encoding the biosynthesis of the zeamine antibiotics was cloned and sequenced and shown to encode FAS, PKS as well as NRPS related enzymes in addition to putative tailoring and export enzymes. Interestingly, several genes show strong homology to the pfa cluster of genes involved in the biosynthesis of long chain polyunsaturated fatty acids in marine bacteria. We postulate that a mixed FAS/PKS and a hybrid NRPS/PKS assembly line each synthesize parts of the backbone that are linked together post-assembly in the case of zeamine and zeamine I. This interaction reflects a unique interplay between secondary lipid and secondary metabolite biosynthesis. Most likely, the zeamine antibiotics are produced as prodrugs that undergo activation in which a nonribosomal peptide sequence is cleaved off.

3 November 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
IVIlse Vandecaetsbeek
Ilse Vandecaetsbeek
MTMieke Trekels
Mieke Trekels
MMMarc De Maeyer
Marc De Maeyer
HCHugo Ceulemans
Hugo Ceulemans
BLBringmeON Eveline Lescrinier
BringmeON Eveline Lescrinier
PVPeter Vangheluwe
Peter Vangheluwe
Sarco(endo)plasmic reticulum Ca 2+ ATPase (SERCA) Ca 2+ transporters pump cytosolic Ca 2+ into the endoplasmic reticulum, maintaining a Ca 2+ gradient that controls vital cell functions ranging from proliferation to death. To meet the physiological demand of the cell, SERCA activity is regulated by adjusting the affinity for Ca 2+ ions. Of all SERCA isoforms, the housekeeping SERCA2b isoform displays the highest Ca 2+ affinity because of a unique C-terminal extension (2b-tail). Here, an extensive structure–function analysis of SERCA2b mutants and SERCA1a2b chimera revealed how the 2b-tail controls Ca 2+ affinity. Its transmembrane (TM) segment (TM11) and luminal extension functionally cooperate and interact with TM7/TM10 and luminal loops of SERCA2b, respectively. This stabilizes the Ca 2+ -bound E1 conformation and alters Ca 2+ -transport kinetics, which provides the rationale for the higher apparent Ca 2+ affinity. Based on our NMR structure of TM11 and guided by mutagenesis results, a structural model was developed for SERCA2b that supports the proposed 2b-tail mechanism and is reminiscent of the interaction between the α- and β-subunits of Na + ,K + -ATPase. The 2b-tail interaction site may represent a novel target to increase the Ca 2+ affinity of malfunctioning SERCA2a in the failing heart to improve contractility.